Regencell Bioscience [RGC] vs Haleon Plc - ADR [HLN] Detailed Stock Comparison
Regencell Bioscience
NASDAQ
Loading...
Haleon Plc - ADR
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Regencell Bioscience wins in 3 metrics, Haleon Plc - ADR wins in 9 metrics, with 0 ties. Haleon Plc - ADR appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Regencell Bioscience | Haleon Plc - ADR | Better |
|---|---|---|---|
| P/E Ratio (TTM) | N/A | 21.58 | N/A |
| Price-to-Book Ratio | 960.00 | 5.48 | Haleon Plc - ADR |
| Debt-to-Equity Ratio | 0.01 | 53.41 | Regencell Bioscience |
| PEG Ratio | N/A | 23.12 | N/A |
| EV/EBITDA | -1,664.45 | 35.81 | Regencell Bioscience |
| Profit Margin (TTM) | 0.00% | 13.81% | Haleon Plc - ADR |
| Operating Margin (TTM) | 0.00% | 22.21% | Haleon Plc - ADR |
| EBITDA Margin (TTM) | N/A | 22.21% | N/A |
| Return on Equity | -47.77% | 9.38% | Haleon Plc - ADR |
| Return on Assets (TTM) | -30.65% | 4.61% | Haleon Plc - ADR |
| Free Cash Flow (TTM) | $-4.01M | $1.98B | Haleon Plc - ADR |
| Dividend Yield | N/A | 1.63% | N/A |
| 1-Year Return | 5,863.64% | -0.31% | Regencell Bioscience |
| Price-to-Sales Ratio (TTM) | N/A | 3.95 | N/A |
| Enterprise Value | $6.64B | $126.86B | Haleon Plc - ADR |
| EV/Revenue Ratio | N/A | 8.53 | N/A |
| Gross Profit Margin (TTM) | N/A | 55.38% | N/A |
| Revenue per Share (TTM) | N/A | $2 | N/A |
| Earnings per Share (Diluted) | $-0.01 | $0.45 | Haleon Plc - ADR |
| Beta (Stock Volatility) | 2.19 | 0.24 | Haleon Plc - ADR |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Regencell Bioscience vs Haleon Plc - ADR Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Regencell Bioscience | 3.31% | -6.08% | -4.23% | 24.01% | 13,020.00% | 9,992.31% |
| Haleon Plc - ADR | -0.52% | 1.15% | -0.82% | -9.56% | -3.40% | 2.22% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Regencell Bioscience | 5,863.64% | 1,443.53% | 4,585.71% | 4,585.71% | 4,585.71% | 4,585.71% |
| Haleon Plc - ADR | -0.31% | 61.37% | 30.23% | 30.23% | 30.23% | 30.23% |
Performance & Financial Health Analysis: Regencell Bioscience vs Haleon Plc - ADR
| Metric | RGC | HLN |
|---|---|---|
| Market Information | ||
| Market Cap | $6.65B | $43.57B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 311,130 | 9,787,791 |
| 90 Day Avg. Volume | 1,546,083 | 11,244,710 |
| Last Close | $13.12 | $9.65 |
| 52 Week Range | $0.09 - $83.60 | $8.86 - $11.42 |
| % from 52W High | -84.31% | -15.50% |
| All-Time High | $950.00 (May 30, 2025) | $11.42 (Jun 02, 2025) |
| % from All-Time High | -98.62% | -15.50% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | -0.01% |
| Quarterly Earnings Growth | N/A | 0.33% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.14% |
| Operating Margin (TTM) | 0.00% | 0.22% |
| Return on Equity (TTM) | -0.48% | 0.09% |
| Debt to Equity (MRQ) | 0.01 | 53.41 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.01 | $1.77 |
| Cash per Share (MRQ) | N/A | $0.08 |
| Operating Cash Flow (TTM) | $-3,881,392 | $3.35B |
| Levered Free Cash Flow (TTM) | $-4,301,837 | $2.59B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.63% |
| Last 12-Month Dividend | N/A | $0.17 |
Valuation & Enterprise Metrics Analysis: Regencell Bioscience vs Haleon Plc - ADR
| Metric | RGC | HLN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | N/A | 21.58 |
| Forward P/E | N/A | 23.12 |
| PEG Ratio | N/A | 23.12 |
| Price to Sales (TTM) | N/A | 3.95 |
| Price to Book (MRQ) | 960.00 | 5.48 |
| Market Capitalization | ||
| Market Capitalization | $6.65B | $43.57B |
| Enterprise Value | $6.64B | $126.86B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 8.53 |
| Enterprise to EBITDA | -1,664.45 | 35.81 |
| Risk & Other Metrics | ||
| Beta | 2.19 | 0.24 |
| Book Value per Share (MRQ) | $0.01 | $1.77 |
Financial Statements Comparison: Regencell Bioscience vs Haleon Plc - ADR
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | RGC | HLN |
|---|---|---|
| Revenue/Sales | N/A | $2.76B |
| Cost of Goods Sold | N/A | $1.23B |
| Gross Profit | N/A | $1.53B |
| Research & Development | N/A | $78.00M |
| Operating Income (EBIT) | N/A | $350.00M |
| EBITDA | N/A | $362.00M |
| Pre-Tax Income | N/A | $288.00M |
| Income Tax | N/A | $66.00M |
| Net Income (Profit) | N/A | $222.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | RGC | HLN |
|---|---|---|
| Cash & Equivalents | $2.96M | $2.20B |
| Total Current Assets | $8.11M | $5.72B |
| Total Current Liabilities | $193,578 | $5.81B |
| Long-Term Debt | $25,934 | $8.62B |
| Total Shareholders Equity | $8.22M | $16.22B |
| Retained Earnings | $-21.62M | $27.27B |
| Property, Plant & Equipment | $84,780 | $0 |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | RGC | HLN |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | RGC | HLN |
|---|---|---|
| Shares Short | 2.25M | 17.45M |
| Short Ratio | 1.15 | 1.39 |
| Short % of Float | 0.02% | 0.00% |
| Average Daily Volume (10 Day) | 311,130 | 9,787,791 |
| Average Daily Volume (90 Day) | 1,546,083 | 11,244,710 |
| Shares Outstanding | 13.01M | 9.12B |
| Float Shares | 18.43M | 8.95B |
| % Held by Insiders | 0.96% | 0.00% |
| % Held by Institutions | 0.00% | 0.13% |
Dividend Analysis & Yield Comparison: Regencell Bioscience vs Haleon Plc - ADR
| Metric | RGC | HLN |
|---|---|---|
| Last 12-Month Dividend | N/A | $0.17 |
| Last 12-Month Dividend Yield | N/A | 1.63% |
| 3-Year Avg Annual Dividend | N/A | $0.11 |
| 3-Year Avg Dividend Yield | N/A | 0.91% |
| 3-Year Total Dividends | N/A | $0.34 |
| Ex-Dividend Date | N/A | Apr 25, 2025 |